A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.

The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.

The U.S. Food and Drug Administration has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine ...

It’s taken nearly a decade for the U.S. FDA to go from zero to 60 in approving biosimilars. Currently, 63 biosimilars have been approved in the U.S., thanks to 18 new approvals in 2024 that stretched ...

The biosimilar landscape continues to expand, with 2024 delivering a wave of exciting approvals across multiple therapeutic areas. Last year alone saw the FDA green light some firsts for biosimilars ...

The Trump administration's freeze on Health and Human Services data is causing concern among officials in the Lane County ...

In July 2024, the FDA approved a third antibody for Alzheimer ... And finally, researchers at Arizona State University and Banner Alzheimer’s Institute published a study in December that ...

Riverwater Partners, an investment management company, released its “Sustainable Value Strategy” Q4 2024 investor letter. A copy of the letter can be downloaded here.

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

President Donald Trump on Saturday finalized tariffs, set to go into effect on Tuesday, at 10 percent on all Chinese goods, ...